Diminished Ovarian Reserve
Conditions
Interventions
Control group:Conventional western medicine treatment
Experimental group:Conventional western medicine treatment combined with traditional Chinese herbal medicine therapy
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
Female
Age
35 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1.Female aged =35 years and <45 years; 2.Menstrual cycle between 21 and 35 days; 3.Meets the diagnostic criteria for diminished ovarian reserve (DOR); 4.Meets the diagnostic criteria for infertility due to kidney deficiency according to Traditional Chinese Medicine (TCM); 5.Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1.Premature ovarian failure or ovarian resistance syndrome; 2.Untreated uterine malformations or abnormalities such as double uterus or septate uterus (complete or incomplete); 3.Untreated unilateral or bilateral hydrosalpinx confirmed by hysterosalpingography; 4.Intrauterine adhesions endometriosis adenomyosis or endometrial lesions (e.g. submucosal fibroids endometrial polyps) or uterine fibroids >4 cm; 5.Endocrine disorders affecting ovulation including polycystic ovary syndrome hyperprolactinemia hyperandrogenism hypothyroidism or adrenal dysfunction; 6.Infertility due to ovarian dysfunction caused by immune factors genetic factors or congenital physiological defects; 7.History of pelvic radiotherapy; 8.Known or suspected malignancy related to sex hormones; 9.Allergy to or intolerance of medications used in the study; 10.Contraindications to assisted reproductive technology or pregnancy such as uncontrolled liver or kidney dysfunction diabetes hypertension thyroid diseases symptomatic heart disease moderate to severe anemia history of malignancy thromboembolism or a tendency toward thrombosis severe mental disorders acute infections of the urogenital system sexually transmitted diseases substance abuse exposure to teratogenic radiation toxic substances or medications (e.g. corticosteroids adrenergic drugs antibiotics antihypertensives cardiovascular or antiviral drugs) during the study period or uterine abnormalities that preclude pregnancy or systemic diseases that make pregnancy intolerable; 11.Use of other kidney-tonifying or interfering Chinese herbal medicines or compounds within the past 30 days; 12.Patients deemed unsuitable for the study by the researchers; 13.Participation in other clinical trials; 14.Refusal to participate in the study or failure to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-Müllerian Hormone;Inhibin B; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum levels of Superoxide Dismutase, Malondialdehyde, and Glutathione Peroxidase;Number of obtained eggs;Rate of high-quality embryos;Clinical pregnancy rate;Traditional Chinese Medicine syndrome Score; | — |
Countries
China
Contacts
Public ContactYang Ye
Peking University Third Hospital
Outcome results
None listed